REMARKS

The applicant has studied the Office Action dated July 25, 1995. It is submitted that the application is in condition for allowance. By virtue of this response, claims 1-58 are pending and no claims are withdrawn from consideration. Reconsideration and allowance of all of the claims in view of the following remarks are respectfully requested.

Claims 1-58 were rejected under 35 U.S.C. § 102(b) as being anticipated by Leslie et al. This rejection is respectfully traversed.

The Leslie et al. reference discloses a device that uses an electronic motor to infuse a specified amount of medication over a period of time. The dosage is set by a keypad which is separate and apart from the device that actually infuses the medication. The Leslie et al. reference only provides memory for a cumulative total of the medication delivered and does not keep track of each individual administered amount of medication that have been previously injected for later recall, as recited in the claims. The Leslie et al. reference does not disclose the use of blood characteristic monitors.

Claim 1 recites "an injection mechanism including an actuator for setting the dosage and administering an injection ... and a memory device coupled to the processor to store the value equal to the dosage determined by the processor along with other values corresponding to previously injected dosages for later recall" (emphasis added). The Leslie et al. reference does not disclose, teach or suggest an injection device that uses a single actuator to set both the dosage and administer the injection. Also, the Leslie et al. reference does not disclose, teach or suggest using a memory device to store the current value equal to the dosage as well as other values corresponding to previously injected dosages. Thus, the rejection of claims 1-8 should be withdrawn.

Claim 9 recites "a blood characteristic monitor," "a processor" and "a medication injector". A blood characteristic monitor is used to determine the amount of glucose, hormone

levels, cholesterol levels or the like (see page 10, line 24 to page 11, line 4 of the application). These features are not disclosed, taught or suggested by the Leslie et al. reference. Thus, the rejection of claim 9, and claims 10-17 and 30-35 that depend from claim 9, should be withdrawn.

Claim 18 recites "the injection end of the injection needle extending beyond the open end of the hollow cylindrical cover <u>such that the open end of the hollow cylindrical cover contacts the skin during an injection</u>" (emphasis added). The Leslie et al. reference does not disclose, teach or suggest a hollow cylindrical cover that is attached to the base to protect the user from accidental pin pricks and which contacts the user's skin during an injection. In fact, the Leslie et al. reference only discloses the use of lure connectors to infuse the medication into the body. Thus, the rejection of claim 18, and claims 19-20 that depend from claim 18, should be withdrawn.

Claim 22 recites "a blood characteristic monitor," "a processor" and "a clock." A blood characteristic monitor is used to determine the amount of glucose, hormone levels, cholesterol levels or the like (see page 10, line 24 to page 11, line 4 of the application). These features are not disclosed, taught or suggested by the Leslie et al. reference. Thus, the rejection of claim 21, and claims 22-29 that depend from claim 21, should be withdrawn.

Claim 36 recites "a characteristic monitor," "a processor" and "an injector". A characteristic monitor is used to determine the amount of glucose, hormone levels, cholesterol levels or the like (see page 10, line 24 to page 11, line 4 of the application). Method claim 51 recites similar language. These features are not disclosed, taught or suggested by the Leslie et al. reference. Thus, the rejection of claims 36 and 51, and claims 37-50 and 52-58 that depend from claims 36 and 51 respectively, should be withdrawn.

Therefore, it is respectfully submitted that the rejection of claims 1-58 under 35 U.S.C. § 102(b) should be withdrawn.